Cooper Heart Names Arrhythmia Device Program Director

Evolving cardiovascular patient management has led to a significant increase in the number of patients who would benefit from device therapy. These changes were the impetus for the recent development of an Arrhythmia Device Program at the Cooper Heart Institute. John Andriulli, D.O., a cardiologist, was appointed as director to manage the growing implantable device service.

“Dr. Andriulli brings an exceptional level of clinical acumen and technical expertise to the Cooper Heart Institute,” says Joseph Parrillo, M.D., director of the Cooper Heart Institute. “The field of device implantation is experiencing tremendous growth in both the numbers and complexity of devices. Dr. Andriulli will assist us in developing a program that meets the device needs of the South Jersey region,” he added.

A graduate of the University of Medicine and Dentistry at the School of Osteopathic Medicine, UMDNJ-SOM, Dr. Andriulli completed his residency and cardiology fellowship at UMDNJ-SOM at the Kennedy Health System in Stratford, New Jersey. He is board certified in internal medicine and cardiology, and is a Fellow of the American College of Cardiology. Dr. Andriulli is also certified in pacing and implantable cardiovertor defibrillators from the North American Society of Pacing and Electrophysiology (NASPE) and is a physician educator and industry preceptor for device implantation.

In addition to his clinical responsibilities, Dr. Andriulli is the principal investigator for several research protocols being conducted at the Cooper Heart Institute. One of these trials, TRENDS, is a clinical study designed to determine if device trending data collected from implantable cardiovertor defibrillators, implantable pulse generators or cardiac resynchronization devices is predictive of occurrences and clinical outcomes in patients with atrial tachyarrhythmias. In addition, he is the principal investigator for a clinical trial entitled: BiVentricular Pacing in Heart Failure Patients with Atrioventricular (BLOCK HF) Study. This outcomes trial will compare the progression of heart failure in patients with bi-ventricular pacing versus right ventricular pacing. The patient population will include patients with mild to moderate heart failure and AV Block.

“Device implantation is now an integral part of cardiovascular disease management,” says Dr. Andriulli. “Our goal is to provide patients with the most advanced and effective diagnostic and therapeutic options. Device therapy is now an essential component of these options.”

To contact Dr. Andriulli, please call: (856) 435-8842.